Ii-Key hybrid polypeptide and preparation method and application of tumor vaccine of Ii-Key hybrid polypeptide

Abstract

The invention discloses an Ii-Key hybrid polypeptide. LRMK tetrapeptide in the amino acid sequence of a stable polypeptide chain (Ii) of MHC class II molecules can be linked by polypeptide recognizedby TH cells, shows MHC class II molecule binding efficacy greater than 250 times in vitro, and is easier to recognize and present by antigen presenting cells. The invention provides a preparation method of a hybrid polypeptide tumor vaccine and application of a combination of the hybrid polypeptide tumor vaccine and an immunologic adjuvant, namely granulocyte-macrophage colony stimulating factor (GM-CSF) to treatment of cancers. The hybrid polypeptide tumor vaccine disclosed by the invention is an efficient cancer immunotherapy vaccine for activating an autoimmune system with a latest mechanism. The Ii-Key hybrid polypeptide tumor vaccine provided by the invention has the advantage of improved anti-cancer effect.

Description

technical field [0001] The invention relates to the technical field of antitumor drugs, in particular to an Ii-Key hybrid polypeptide tumor vaccine. Background technique [0002] Prostate cancer (PCa) is a relatively common malignant tumor of the male reproductive system, and its incidence rate ranks second among all male malignant tumors worldwide; in the United States, its incidence rate has surpassed lung cancer and become the first A tumor that seriously threatens men's health. Although the incidence of prostate cancer in my country is lower than that in western countries, in recent years, with the aging of the population, the improvement of people's health awareness, the change of diet structure and the continuous improvement of diagnostic technology, the incidence and mortality of prostate cancer have shown a significant upward trend. It is becoming an important malignant tumor affecting the health of men in our country. Taking Shanghai as an example, the incidence of...

AI Technical Summary

Problems solved by technology

Second-line endocrine therapy and chemotherapy (such as docetaxel, cabazitaxel, etc.) can delay tumor progression to a certain extent and prolong patient survival, but they still cannot completely kill tumor cells

25% of BCa found to have high expression of HER2 / neu, which often leads to poor prognosis

[0012] Preliminary results from clinical trials of the vaccine confirm the safety of the vaccine, but also demonstrate the lack of immune response if the vaccine dose is low and / or given infrequently

Moreover, peptide-specific cytotoxic T lymphocyte (CTL) responses were extremely weak 6 months after the end of vaccination

Images